INmune Bio (NASDAQ:INMB) Upgraded at Lucid Cap Mkts

Lucid Cap Mkts upgraded shares of INmune Bio (NASDAQ:INMB) from a hold rating to a strong-buy rating in a research report report published on Wednesday,Zacks.com reports.

Separately, Wall Street Zen raised INmune Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, INmune Bio has an average rating of “Hold” and a consensus target price of $8.00.

INmune Bio Trading Down 1.5%

Shares of INMB opened at $1.31 on Wednesday. The firm has a fifty day simple moving average of $1.48 and a two-hundred day simple moving average of $1.71. The firm has a market cap of $34.82 million, a PE ratio of -0.62 and a beta of 0.77. INmune Bio has a 1-year low of $1.16 and a 1-year high of $11.64.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. PNC Financial Services Group Inc. purchased a new position in shares of INmune Bio during the 2nd quarter worth $87,000. Quadrature Capital Ltd purchased a new stake in shares of INmune Bio in the 4th quarter worth $26,000. Jain Global LLC bought a new position in INmune Bio in the 4th quarter worth $66,000. Charles Schwab Investment Management Inc. raised its holdings in INmune Bio by 20.1% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 50,252 shares of the company’s stock worth $78,000 after purchasing an additional 8,427 shares during the period. Finally, Wells Fargo & Company MN lifted its position in INmune Bio by 79.0% during the fourth quarter. Wells Fargo & Company MN now owns 24,857 shares of the company’s stock valued at $39,000 after purchasing an additional 10,970 shares in the last quarter. 12.72% of the stock is currently owned by institutional investors.

INmune Bio Company Profile

INmune Bio, Inc is a clinical-stage immunology company based in San Diego, California, focused on harnessing the innate immune system to combat a range of serious diseases. The company’s research and development efforts concentrate on modulating cellular pathways to restore and enhance the body’s natural defenses, particularly in oncology and neurodegenerative conditions.

The company’s lead therapeutic candidate, XPro1595 (also referred to as INB03), is a proprietary selective inhibitor of soluble tumor necrosis factor (TNF) designed to reduce chronic inflammation without impairing membrane-bound TNF functions.